Loading clinical trials...
Loading clinical trials...
A Phase III Study of IRESSA in Combination With Intravesical BCG Versus Intravesical BCG Alone in High Risk Superficial Transitional Cell Carcinoma of the Bladder
Conditions
Interventions
BCG vaccine
gefitinib
+1 more
Locations
6
Canada
Clinical Research Unit at Vancouver Coastal
Vancouver, British Columbia, Canada
Hamilton and District Urology Association
Hamilton, Ontario, Canada
London Regional Cancer Program
London, Ontario, Canada
Univ. Health Network-Princess Margaret Hospital
Toronto, Ontario, Canada
CHUQ-Pavillon Hotel-Dieu de Quebec
Québec, Quebec, Canada
Centre hospitalier universitaire de Sherbrooke
Sherbrooke, Quebec, Canada
Start Date
January 4, 2007
Primary Completion Date
January 6, 2012
Completion Date
January 6, 2012
Last Updated
August 4, 2023
NCT04235764
NCT03375307
NCT00026884
NCT07061964
NCT07050771
NCT04585750
Lead Sponsor
NCIC Clinical Trials Group
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions